| Synonym |
| Thai / English name |
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 10 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 or NAC dose-dependently inhibited the cisplatin-induced increase in HO-1 and NQO-1 in normal cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 20 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 or NAC dose-dependently inhibited the cisplatin-induced increase in HO-1 and NQO-1 in normal cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 25 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 downregulated the expression of HO-1 and NQO-1 to less than their basal level in cisplatin-treated CT-26 cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 50 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 downregulated the expression of HO-1 and NQO-1 to less than their basal level in cisplatin-treated CT-26 cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 10 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 or NAC inhibited the cisplatin-induced translocation of Nrf2 in normal cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 50 micrograms cisplatin + 20 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3 or NAC inhibited the cisplatin-induced translocation of Nrf2 in normal cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 25 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3, dose-dependently reduced the accumulation of nuclear Nrf2 level in cisplatin-treated cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : ginsenoside Rg3Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 500 micrograms cisplatin + 50 micrograms Rg3Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Cisplatin*/CDDPDose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment with Rg3, dose-dependently reduced the accumulation of nuclear Nrf2 level in cisplatin-treated cancer cells.Note : CT-26 mouse colon cancer cells (2x10^6 cells) suspended in 0.1 ml phosphate buffered saline (PBS) were subcutaneously injected into the right flanks of the mice. Twenty-four hours later, the mice were given Rg3 (5 or 10 mg/kg body weight (BW)) in PBS via oral gavage. Two hours later, cisplatin (2 or 5 mg/kg BW) dissolved in PBS was intraperitoneally injected. Rg3 and/or cisplatin were administered once per day for 15 days.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : Panax ginseng (PGS) water extractType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : PGS extract 0.81 g/kg, twice dailyDuration : ten consecutive daysType of interaction : PharmacokineticsInteraction with drug : 5-fluorouracil (5-FU)*/Fluorouracil/FUDose/Conc.(drug) : -Result : PositiveRemark : Result: The time to reach the maximum concentration (Tmax) was 14.56 min in the PGS pretreated groups, and 10.37 min in the control gruop. After pretreatment with PGS, the elimination half-life of 5-FU was significantly increased from 79.17 to 125.72, which was an increase of approximately 58.8% compared with the control. The results indicate that PGS may affect the elimination of 5-FU.
Part Used : รากActivity : DRUG INTERACTIONSolvent/Active Compound : 20(S)-protopanaxatriol (ppt)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : ppt 100 mMDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: ppt exhibited strong noncompetitive inhibition towards UGT1A1 and competitive inhibition towards UGT2B7. The inhibition kinetic parameters (Ki) were calculated to be 8.8 and 2.2 mM for UGT1A1 and UGT2B7, respectively. Using the maximum plasma concentration of ppt, the alteration of area under the concentration-time curve as calculated to be 20% and 70% respectively for UGT1A1-mediated and UGT2B7-mediated metabolism.Note : Due to the lack of specific substrates for various UGT isoforms, the nonspecific probe substrate 4-MU and recombinant UGT enzymes were brought to bear on the present study.
